TherapeuticsMD, Inc. Selling, General and Administrative Expense
TherapeuticsMD, Inc. (TXMD) reported Selling, General and Administrative Expense of $1.55 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-08-12
- TherapeuticsMD, Inc. selling, general and administrative expense for the quarter ending 2025-06-30 was $1.55M, a 1.96% decline year-over-year.
- TherapeuticsMD, Inc. selling, general and administrative expense for the quarter ending 2025-03-31 was $1.08M, a 18.23% decline year-over-year.
- TherapeuticsMD, Inc. selling, general and administrative expense for the quarter ending 2024-06-30 was $1.58M, a 43.11% decline year-over-year.
- TherapeuticsMD, Inc. selling, general and administrative expense for the quarter ending 2024-03-31 was $1.32M, a 56.74% decline year-over-year.
- TherapeuticsMD, Inc. selling, general and administrative expense for fiscal 2024 was $4.74M, a 46.71% decline from fiscal 2023.
- TherapeuticsMD, Inc. selling, general and administrative expense for fiscal 2023 was $8.90M.
- TherapeuticsMD, Inc. selling, general and administrative expense for fiscal 2020 was $192.96M, a 10.83% increase from fiscal 2019.
- TherapeuticsMD, Inc. selling, general and administrative expense for fiscal 2019 was $174.11M, a 50.11% increase from fiscal 2018.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2025-06-30 | $1.55M 10-Q · filed 2025-08-12 | $3.04M 10-Q · filed 2025-08-12 | |||||
| 2025-03-31 | $1.08M 10-Q · filed 2025-05-13 | ||||||
| 2024-12-31 | $4.74M 10-K · filed 2025-03-27 | ||||||
| 2024-06-30 | $1.58M 10-Q · filed 2025-08-12 | $1.23M 10-Q · filed 2024-08-12 | $3.30M 10-Q · filed 2025-08-12 | $2.56M 10-Q · filed 2024-08-12 | $4.38M derived: sum of 3 quarters · filed 2025-08-12 | $5.97M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $1.32M 10-Q · filed 2025-05-13 | $2.80M derived: sum of 2 quarters · filed 2025-05-13 | $4.39M derived: sum of 3 quarters · filed 2025-05-13 | $7.17M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $3.07M derived: sum of 2 quarters · filed 2025-03-27 | $5.85M derived: sum of 3 quarters · filed 2025-03-27 | $8.90M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $1.59M 10-Q · filed 2023-11-14 | $4.37M derived: sum of 2 quarters · filed 2024-08-12 | $7.43M 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $2.78M 10-Q · filed 2024-08-12 | $5.84M 10-Q · filed 2024-08-12 | |||||
| 2023-03-31 | $3.06M 10-Q · filed 2023-05-15 | ||||||
| 2022-09-30 | $14.25M 10-Q · filed 2023-11-14 | $28.82M derived: sum of 2 quarters · filed 2023-11-14 | $46.37M 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | $14.57M 10-Q · filed 2023-08-14 | $32.12M 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | $17.55M 10-Q · filed 2023-05-15 | ||||||
| 2021-03-31 | $42.41M 10-Q · filed 2021-05-06 | $91.35M derived: sum of 2 quarters · filed 2021-05-06 | $130.10M derived: sum of 3 quarters · filed 2021-05-06 | $178.44M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2020-12-31 | $48.95M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $87.70M derived: sum of 2 quarters · filed 2021-03-04 | $136.04M derived: sum of 3 quarters · filed 2021-03-04 | $192.96M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $38.75M 10-Q · filed 2020-11-09 | $87.09M derived: sum of 2 quarters · filed 2020-11-09 | $144.02M 10-Q · filed 2020-11-09 | $197.01M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2020-06-30 | $48.34M 10-Q · filed 2020-08-07 | $105.27M 10-Q · filed 2020-08-07 | $158.26M derived: sum of 3 quarters · filed 2021-05-06 | $203.39M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2020-03-31 | $57.19M 10-Q · filed 2021-05-06 | $56.93M 10-Q · filed 2020-05-06 | $109.92M derived: sum of 2 quarters · filed 2021-05-06 | $155.05M derived: sum of 3 quarters · filed 2021-05-06 | $196.44M derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $52.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $97.86M derived: sum of 2 quarters · filed 2021-03-04 | $139.25M derived: sum of 3 quarters · filed 2021-03-04 | $174.11M 10-K · filed 2021-03-04 | |||
| 2019-09-30 | $45.13M 10-Q · filed 2020-11-09 | $86.51M derived: sum of 2 quarters · filed 2020-11-09 | $121.38M 10-Q · filed 2020-11-09 | $156.79M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-06-30 | $41.39M 10-Q · filed 2020-08-07 | $76.25M 10-Q · filed 2020-08-07 | $111.66M derived: sum of 3 quarters · filed 2021-03-04 | $142.02M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-03-31 | $34.86M 10-Q · filed 2020-05-06 | $70.27M derived: sum of 2 quarters · filed 2021-03-04 | $100.63M derived: sum of 3 quarters · filed 2021-03-04 | $130.10M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2018-12-31 | $35.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $65.76M derived: sum of 2 quarters · filed 2021-03-04 | $95.23M derived: sum of 3 quarters · filed 2021-03-04 | $115.99M 10-K · filed 2021-03-04 | |||
| 2018-09-30 | $30.35M 10-Q · filed 2019-11-08 | $59.82M derived: sum of 2 quarters · filed 2019-11-08 | $80.58M 10-Q · filed 2019-11-08 | $94.76M derived: sum of 4 quarters · filed 2020-02-24 | |||
| 2018-06-30 | $29.47M 10-Q · filed 2019-08-09 | $50.22M 10-Q · filed 2019-08-09 | $64.40M derived: sum of 3 quarters · filed 2020-02-24 | $76.46M derived: sum of 4 quarters · filed 2020-02-24 | |||
| 2018-03-31 | $20.76M 10-Q · filed 2019-05-08 | $34.94M derived: sum of 2 quarters · filed 2020-02-24 | $46.99M derived: sum of 3 quarters · filed 2020-02-24 | $61.62M derived: sum of 4 quarters · filed 2020-02-24 | |||
| 2017-12-31 | $14.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $26.24M derived: sum of 2 quarters · filed 2020-02-24 | $40.87M derived: sum of 3 quarters · filed 2020-02-24 | $57.70M 10-K · filed 2020-02-24 | |||
| 2017-09-30 | $12.06M 10-Q · filed 2018-11-08 | $26.69M derived: sum of 2 quarters · filed 2018-11-08 | $43.52M 10-Q · filed 2018-11-08 | $59.85M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-06-30 | $14.63M 10-Q · filed 2018-07-30 | $31.47M 10-Q · filed 2018-07-30 | $47.80M derived: sum of 3 quarters · filed 2019-02-27 | $62.52M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-03-31 | $16.84M 10-Q · filed 2018-05-07 | $33.17M derived: sum of 2 quarters · filed 2019-02-27 | $47.89M derived: sum of 3 quarters · filed 2019-02-27 | $58.51M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2016-12-31 | $16.33M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $31.05M derived: sum of 2 quarters · filed 2019-02-27 | $41.67M derived: sum of 3 quarters · filed 2019-02-27 | $51.35M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | $14.72M 10-Q · filed 2017-11-07 | $25.34M derived: sum of 2 quarters · filed 2017-11-07 | $35.02M 10-Q · filed 2017-11-07 | $43.65M derived: sum of 4 quarters · filed 2018-02-23 | |||
| 2016-06-30 | $10.62M 10-Q · filed 2017-08-03 | $20.30M 10-Q · filed 2017-08-03 | $28.93M derived: sum of 3 quarters · filed 2018-02-23 | $35.99M derived: sum of 4 quarters · filed 2018-02-23 | |||
| 2016-03-31 | $9.68M 10-Q · filed 2017-05-03 | $18.31M derived: sum of 2 quarters · filed 2018-02-23 | $25.37M derived: sum of 3 quarters · filed 2018-02-23 | $32.24M derived: sum of 4 quarters · filed 2018-02-23 | |||
| 2015-12-31 | $8.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $15.69M derived: sum of 2 quarters · filed 2018-02-23 | $22.56M derived: sum of 3 quarters · filed 2018-02-23 | $28.72M 10-K · filed 2018-02-23 | |||
| 2015-09-30 | $7.06M 10-Q · filed 2016-11-04 | $13.93M derived: sum of 2 quarters · filed 2016-11-04 | $20.09M 10-Q · filed 2016-11-04 | $25.60M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | $6.87M 10-Q · filed 2016-08-05 | $13.03M 10-Q · filed 2016-08-05 | $18.54M derived: sum of 3 quarters · filed 2017-02-28 | $24.59M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | $6.16M 10-Q · filed 2016-05-05 | $11.68M derived: sum of 2 quarters · filed 2017-02-28 | $17.72M derived: sum of 3 quarters · filed 2017-02-28 | $23.26M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $11.56M derived: sum of 2 quarters · filed 2017-02-28 | $17.09M derived: sum of 3 quarters · filed 2017-02-28 | $22.12M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $6.04M 10-Q · filed 2015-11-05 | $11.58M derived: sum of 2 quarters · filed 2015-11-05 | $16.61M 10-Q · filed 2015-11-05 | $21.17M derived: sum of 4 quarters · filed 2016-02-26 | |||
| 2014-06-30 | $5.54M 10-Q · filed 2015-08-07 | $10.57M 10-Q · filed 2015-08-07 | $15.13M derived: sum of 3 quarters · filed 2016-02-26 | $19.88M derived: sum of 4 quarters · filed 2016-02-26 | |||
| 2014-03-31 | $5.03M 10-Q · filed 2015-05-07 | $9.59M derived: sum of 2 quarters · filed 2016-02-26 | $14.34M derived: sum of 3 quarters · filed 2016-02-26 | $19.82M derived: sum of 4 quarters · filed 2016-02-26 | |||
| 2013-12-31 | $4.56M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $9.31M derived: sum of 2 quarters · filed 2016-02-26 | $14.79M derived: sum of 3 quarters · filed 2016-02-26 | $19.01M 10-K · filed 2016-02-26 | |||
| 2013-09-30 | $4.75M 10-Q · filed 2014-11-07 | $10.23M derived: sum of 2 quarters · filed 2014-11-07 | $14.46M 10-Q · filed 2014-11-07 | $19.69M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2013-06-30 | $5.48M 10-Q · filed 2014-08-07 | $10.00M 10-Q · filed 2014-08-07 | $14.93M derived: sum of 3 quarters · filed 2015-03-12 | $17.86M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2013-03-31 | $4.53M 10-Q · filed 2014-05-07 | $9.46M derived: sum of 2 quarters · filed 2015-03-12 | $12.38M derived: sum of 3 quarters · filed 2015-03-12 | $15.95M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2012-12-31 | $4.93M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $7.85M derived: sum of 2 quarters · filed 2015-03-12 | $11.43M derived: sum of 3 quarters · filed 2015-03-12 | $14.07M 10-K · filed 2015-03-12 | |||
| 2012-09-30 | $2.92M 10-Q · filed 2013-11-05 | $3.29M 10-Q · filed 2012-11-13 | $6.50M derived: sum of 2 quarters · filed 2013-11-05 | $9.14M 10-Q · filed 2013-11-05 | $9.69M 10-Q · filed 2012-11-13 | $11.91M derived: sum of 4 quarters · filed 2014-03-05 | |
| 2012-06-30 | $3.57M 10-Q · filed 2013-08-07 | $6.40M 10-Q · filed 2013-08-07 | $8.99M derived: sum of 3 quarters · filed 2014-03-05 | $10.62M derived: sum of 4 quarters · filed 2014-03-05 | |||
| 2012-03-31 | $2.83M 10-Q · filed 2013-05-10 | $5.41M derived: sum of 2 quarters · filed 2014-03-05 | $7.05M derived: sum of 3 quarters · filed 2014-03-05 | $8.25M derived: sum of 4 quarters · filed 2014-03-05 | |||
| 2011-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-05 | $4.22M derived: sum of 2 quarters · filed 2014-03-05 | $5.42M derived: sum of 3 quarters · filed 2014-03-05 | $6.41M 10-K · filed 2014-03-05 | |||
| 2011-09-30 | $1.63M 10-Q · filed 2012-11-13 | $2.83M derived: sum of 2 quarters · filed 2012-11-13 | $3.82M 10-Q · filed 2012-11-13 | ||||
| 2011-06-30 | $1.20M 10-Q · filed 2012-08-09 | $2.19M 10-Q · filed 2012-08-09 | |||||
| 2011-03-31 | $985.12K 10-Q · filed 2012-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |